GlassScriptPhysician profile
Krisha G Shah
NPI 1881349975
$2,024.14
in general payments reported to CMS, 2019-2025
24 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $678 · 2023: $488 · 2024: $712 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $344.36 | 2022-2023 | Farxiga, Breztri, Evusheld |
| Abbvie INC. | $293.81 | 2022-2024 | |
| Novo Nordisk INC | $224.69 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.00 | 2022-2024 | Jardiance |
| Ucb, INC. | $146.28 | 2025 | Bimzelx |
| Daiichi Sankyo INC. | $134.87 | 2022-2024 | Injectafer |
| Lilly USA, LLC | $107.93 | 2022-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $78.27 | 2023-2024 | Trelegy Ellipta, Benlysta, Nucala |
| Astellas Pharma US INC | $70.49 | 2022-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $69.99 | 2022 | |
| Pfizer INC. | $49.49 | 2022-2023 | |
| Amarin Pharma, INC. | $43.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $34.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.19 | 2022 | |
| Silk Road Medical, INC. | $25.06 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.01 | 2024 | |
| Amgen INC. | $17.97 | 2023 | Prolia, Evenity |
| Renalytix Ai, INC. | $17.94 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Scilex Pharmaceuticals INC. | $17.06 | 2023 | Ztlido |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.75 | 2022 | |
| Noven Pharmaceuticals, INC. | $14.64 | 2023 | Xelstrym |
| Sanofi Pasteur INC. | $14.20 | 2023 | |
| Endo Pharmaceuticals INC. | $12.95 | 2023 | Nascobal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krisha Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.